Compare MGM Resorts International (MGM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs TG Therapeutics Inc — how do they compare? MGM Resorts International trades at $29.3 (market cap $7.55B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: MGM Resorts International and TG Therapeutics Inc are close in size by market cap, and MGM Resorts International pays a 0.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and TG Therapeutics Inc for 16 Days on average.
| MGM | TGTX | |
|---|---|---|
Market Cap | $7.55B | $8.16B |
Volume | 5,342,346 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $59.06 |
52-Week Low | $30.00 | $26.94 |
Typical Hold Time | 91 Days | 16 Days |
Enterprise Value | $34.85B | $8.37B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) stock is trading at $29.27, down 2.43% on the day and reflecting significant pressure following the collapse of Barry Diller's $48.30 per share acquisition proposal in late September 2026. The technical picture is bearish, while fundamentals show mixed signals with revenue growth to $17.54B in 2025 but declining net income margins. Analyst sentiment remains predominantly positive with a consensus price target of $48.75, suggesting substantial upside potential from current levels.
The investment case hinges on MGM's ability to execute its strategic initiatives and potentially pursue acquisitions like People Inc. to unlock value. Near-term risks include integration challenges, market volatility, and execution missteps. The current valuation at a P/E of 18.19 and P/S of 0.45 appears reasonable if management can stabilize profitability and navigate the post-deal uncertainty.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
